ROCK1 and neoplasm: The putative mechanism involves the activation of the ROCK1/c‐Myc/PD‐L1 axis, allowing tumor cells to evade immune destruction, consequently diminishing the therapeutic efficacy of anti‐PD‐L1 antibodies.